NuCana plc

NCNA

US67022C2052

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:58:39 2024-05-17 pm EDT			5-day change	1st Jan Change
3.59 ^USD	-2.18%		-0.14%	-51.52%

May. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT
May. 09	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

October 13, 2020 at 04:01 pm EDT

NuCana plc announced the appointment of Bali Muralidhar, M.D., Ph.D. to its Board of Directors.

Latest news about NuCana plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	May. 10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	May. 07	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	May. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
NuCana Completes ADS to Ordinary Share Ratio Change	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
ADRs Slump, VIA Optronics AG Declines 27%	Apr. 15	DJ
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	Mar. 28	MT
NuCana Plans ADS Ratio Change to Comply With Nasdaq Rules; Shares Fall After Hours	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3â-deoxyadenosine (3â-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Companyâs subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.67 USD

Average target price

119.8 USD

Spread / Average Target

+3,165.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUCANA PLC	-51.52%	7.69M
VERTEX PHARMACEUTICALS INCORPORATED	+9.35%	114B
REGENERON PHARMACEUTICALS, INC.	+11.44%	104B
BIONTECH SE	-13.57%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-3.79%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.67%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.52%	12.55B

Bio Therapeutic Drugs

NuCana plc

Equities

NCNA

US67022C2052

Biotechnology & Medical Research

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

Latest news about NuCana plc

Chart NuCana plc

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs